News for Sumitomo Dainippon Pharma Co., Ltd. (DPM.F)

Asian stock markets are mostly lower on Friday following the negative cues overnight from Wall Street as treasury yields spiked in reaction to the highly anticipated Federal Reserve Chair Jerome Powell's remarks, which failed to calm concerns about higher interest rates and inflation.

Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The global schizophrenia drug market accounted for US$ 7.5 Bn in 2020 and is estimated to be US$ 9.8 Bn by 2030 ...

Asian stock markets are exhibiting a mixed trend on Thursday after Wall Street closed mostly lower overnight as largely upbeat economic data added to optimism about the economic recovery, but raised concerns about inflation.

Management Team Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and... | February 13, 2021

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disord...

/PRNewswire/ -- The "Anti-Viral Drug Therapy Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth" report has been added to...

Japan stocks higher at close of trade; Nikkei 225 up 0.40%

Asian stock markets are mixed on Friday, with some of the markets paring early gains despite the overnight rebound on Wall Street. Worries about a liquidity squeeze in China and highly speculative retail trading in the U.

(RTTNews) - The Japanese stock market is advancing on Friday after sharp losses in the previous session and following the overnight rebound on Wal...

According to Coherent Market Insights, the global epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the...

POXEL SA , a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis , today announced that,... | January 14, 2021

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disord...

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including

POXEL SA , a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis , today announced its... | January 5, 2021

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disord...